DEEP AF Feasibility Trial Update Call
November 17, 2011 9:00 a.m. ET
David Drachman - President and CEO
Julie Piton - VP, Finance and CFO
Vivian Cervantes - Kaufman Brothers
Matt Dolan - ROTH Capital Partners
Jan Wald - Morgan Keegan
Kevin Kotler - Broadfin Capital
Good morning and welcome to AtriCure’s call to provide an update on its DEEP AF feasibility trial. [Operator instructions.] I would now like to turn the call over to Mr. David Drachman, president and chief executive officer of AtriCure. Mr. Drachman, please proceed.
Good morning and welcome to AtriCure’s call to provide and update on its DEEP AF feasibility trial. My name is David Drachman, and I will be your coordinator for the call today. With me on the call today is Julie Piton, vice president of finance and administration and chief financial officer. At this time, I would like to turn the call over to Julie for a few introductory comments.
Thank you Dave, and good morning everyone. Before we begin today, let me remind you that the company’s remarks may include forward looking statements. These statements include, but are not limited to those that address activity, events, or developments that AtriCure expects, believes, or anticipates will or may occur in the future, such as revenue and earnings estimates, other predictions of financial performance, launches of new products, and market acceptance of new products.
Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond AtriCure’s control, including, but not limited to, the rate and degree of market acceptance of AtriCure’s products, governmental approvals and other risks and uncertainties described from time to time in AtriCure’s SEC filings.